Guidelines for the Primary Prevention of Stroke

The aim of this updated statement is to provide comprehensive and timely evidence-based recommendations on the prevention of stroke among individuals who have not previously experienced a stroke or transient ischemic attack. Evidence-based recommendations are included for the control of risk factors, interventional approaches to atherosclerotic disease of the cervicocephalic circulation, and antithrombotic treatments for preventing thrombotic and thromboembolic stroke. Further recommendations are provided for genetic and pharmacogenetic testing and for the prevention of stroke in a variety of other specific circumstances, including sickle cell disease and patent foramen ovale.

• EL
  Eli Lilly and Company
• P
  Pfizer
• A
  AstraZeneca
• S
  Sanofi
• BA
  Brigham and Women's Hospital
• B
  Biogen
• UO
  University of Miami
• WF
  Wake Forest University
• RU
  Rush University
• UO
  University of Texas Health Science Center at Houston
• AC
  Amarin Corporation
• YU
  York University
• ID
  IC Design Education Center
• NN
  Novo Nordisk
• NI
  National Institutes of Health
• CP
  Claude Pepper Older Americans Independence Center, Wake Forest School of Medicine
• LM
  Leonard M. Miller School of Medicine
• AV
  Abbott Vascular
• NH
  National Heart, Lung, and Blood Institute
• NI
  National Institute of Neurological Disorders and Stroke
• DS
  Daiichi Sankyo Europe